Stifel analyst James Condulis raised the firm's price target on X4 Pharmaceuticals to $10 from $7.50 and keeps a Buy rating on the shares as the firm transferred coverage of the stock. The firm's "bullish thesis" is based on a view that, after a significant transformation of the company in recent months, X4 "finally has the right team" to develop, launch and sell a hematology-focused asset and necessary capital and strategy through a potential launch in 2028, the new analyst tells investors.
